DoorDash, Inc. Class A Common Stock (DASH)vsMEDIFAST INC (MED)
DASH
DoorDash, Inc. Class A Common Stock
$169.49
-0.63%
CONSUMER CYCLICAL · Cap: $81.96B
MED
MEDIFAST INC
$12.28
-1.68%
CONSUMER CYCLICAL · Cap: $136.07M
Smart Verdict
WallStSmart Research — data-driven comparison
DoorDash, Inc. Class A Common Stock generates 4914% more annual revenue ($15.89B vs $316.93M). DASH leads profitability with a 5.3% profit margin vs -8.1%. MED appears more attractively valued with a PEG of 0.97. DASH earns a higher WallStSmart Score of 48/100 (D+).
DASH
Hold48
out of 100
Grade: D+
MED
Hold45
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.4%
Fair Value
$187.44
Current Price
$169.49
$17.95 discount
Intrinsic value data unavailable for MED.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 35.6% year-over-year
Large-cap with strong market position
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
5.3% margin — thin
Operating margin of 3.9%
Weak financial health signals
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Weak financial health signals
ROE of -10.1% — below average capital efficiency
Revenue declined 27.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : DASH
The strongest argument for DASH centers on Revenue Growth, Market Cap. Revenue growth of 35.6% demonstrates continued momentum. PEG of 1.05 suggests the stock is reasonably priced for its growth.
Bull Case : MED
The strongest argument for MED centers on Price/Book, Altman Z-Score, Debt/Equity. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bear Case : DASH
The primary concerns for DASH are Profit Margin, Operating Margin, Piotroski F-Score. A P/E of 99.5x leaves little room for execution misses.
Bear Case : MED
The primary concerns for MED are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
DASH profiles as a hypergrowth stock while MED is a turnaround play — different risk/reward profiles.
DASH carries more volatility with a beta of 1.89 — expect wider price swings.
DASH is growing revenue faster at 35.6% — sustainability is the question.
DASH generates stronger free cash flow (888M), providing more financial flexibility.
Bottom Line
DASH scores higher overall (48/100 vs 45/100) and 35.6% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DoorDash, Inc. Class A Common Stock
CONSUMER CYCLICAL · INTERNET RETAIL · USA
DoorDash, Inc. operates a logistics platform that connects merchants, consumers, and merchants in the United States and internationally. The company is headquartered in San Francisco, California.
Visit Website →MEDIFAST INC
CONSUMER CYCLICAL · PERSONAL SERVICES · USA
Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.
Visit Website →Compare with Other INTERNET RETAIL Stocks
Want to dig deeper into these stocks?